The ROR1-drug conjugate was also tested in previously treated MCL in a phase 1 trial (NCT03833180) that enrolled 15 MCL case with an ORR of 47% (4 PR and 3 CR) [198]. The gene discussed is ROR1; the disease is mantle cell lymphoma.